Stock Performance and Market Context
On 12 August 2026, Shree Ganesh Biotech India Ltd closed at ₹0.52, exactly matching its 52-week low and representing a 35.8% decline from its 52-week high of ₹0.81. The stock’s day-on-day movement showed a decrease of 1.89%, underperforming the Sensex’s fall of 0.68% on the same day. Over the past week, the stock has declined by 5.45%, compared to a 1.22% drop in the Sensex, while its one-month performance was down 3.70% against a marginal 0.07% gain in the benchmark index.
Longer-term trends reveal a more pronounced deterioration: a 13.33% decline over three months versus a 4.11% gain in the Sensex, a 35.00% drop over one year compared to the Sensex’s 3.25% loss, and a 49.02% fall over three years against the Sensex’s 18.83% rise. Over five years, the stock has plummeted 92.52%, while the Sensex has surged 41.54%. The stock’s year-to-date performance also trails the benchmark, down 16.13% versus the Sensex’s 8.91% decline.
Technical Indicators and Trading Patterns
The technical outlook remains bearish, with the stock trading below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The overall technical trend shifted to bearish on 16 June 2026 at ₹0.58, following a prior mildly bearish phase. Weekly indicators such as MACD and KST signal bearish momentum, while monthly MACD is mildly bullish but offset by bearish Bollinger Bands and KST readings. Immediate support is established at ₹0.52, coinciding with the 52-week low, while resistance levels are noted at ₹0.55 (20-day moving average), ₹0.59 (100-day moving average), and ₹0.62 (200-day moving average).
Delivery volumes have shown some recent increase, with a 24.37% rise in one-day delivery volume compared to the five-day average, and a 6.38% increase over the past month. Despite this, average monthly delivery volumes remain subdued, reflecting limited trading interest.
Financial and Valuation Metrics
Shree Ganesh Biotech India Ltd is classified as a micro-cap company within the Pharmaceuticals & Biotechnology sector. The company’s valuation multiples reflect its challenging financial position. The price-to-book value stands at a low 0.34x, while EV/EBITDA and EV/EBIT ratios are negative at -7.80x, signalling losses at the operating level. The EV/Sales ratio is 2.74x, and EV/Capital Employed is 0.25x. The company is loss-making, with no reported price-to-earnings ratio or PEG ratio available. Dividend metrics are absent, with no dividend yield, payout, or ex-dividend date recorded.
Profitability and Earnings Trends
Recent quarterly results indicate flat financial performance as of June 2026. The company reported its lowest quarterly PBDIT at ₹-0.89 crore and PBT less other income also at ₹-0.89 crore. Earnings per share for the quarter stood at ₹-0.01, marking the lowest level recorded. EBITDA remains negative at ₹-1.76 crore, underscoring ongoing difficulties in generating operating profits.
Over the past year, profits have declined sharply by 86%, contributing to the stock’s 35.00% negative return during the same period. The company’s ability to service debt is constrained, with an average EBIT to interest ratio of 0.35, indicating limited coverage of interest expenses by operating earnings.
Quality and Risk Assessment
The company’s overall quality grade is below average, reflecting weak long-term financial performance. Key quality indicators include a five-year sales decline of 31.22% and a five-year EBIT contraction of 204.98%. Despite these challenges, the company maintains a net cash position, with a negative net debt to equity ratio of -0.12 and no promoter share pledging. Institutional holdings are minimal at 1.42%, with the majority of shares held by non-institutional investors.
Return on equity remains low at an average of 2.62%, signalling limited profitability relative to shareholders’ funds. Return on capital employed is similarly weak at 1.52%. The company’s capital structure is considered good, but growth and management risk factors are rated below average.
Sector and Comparative Performance
Within the broader Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India Ltd’s performance contrasts with sector trends. On the day of the stock’s all-time low, the agriculture sector, which is related but distinct, declined by 2.17%. The stock outperformed its sector by 1.92% on the day, despite its negative price movement, reflecting sector-wide weakness.
Compared to the Sensex, the stock’s underperformance is marked across all time frames, highlighting the severity of its decline relative to the broader market.
Summary of Key Metrics as of 12 August 2026
Market Capitalisation: Micro-cap classification
Mojo Score: 12.0
Mojo Grade: Strong Sell (upgraded from Sell on 8 August 2024)
Price: ₹0.52
52-Week Range: ₹0.52 (low) to ₹0.81 (high)
Day Change: -1.89%
One-Year Performance: -35.00%
Five-Year Performance: -92.52%
EBIT to Interest Ratio (average): 0.35x
Return on Equity (average): 2.62%
Negative EBITDA: ₹-1.76 crore
Conclusion
Shree Ganesh Biotech India Ltd’s share price reaching an all-time low of ₹0.52 on 12 August 2026 reflects a sustained period of financial and market challenges. The company’s weak profitability metrics, negative earnings, and below-average quality assessments underscore the difficulties faced. Technical indicators confirm a bearish trend, while valuation multiples and financial ratios highlight the company’s loss-making status and limited capacity to generate returns. The stock’s performance relative to the Sensex and sector benchmarks further illustrates the extent of its decline over multiple time horizons.
